Physician profile
Eric Edward Holt
NPI 1013070424
$3,164.44
in general payments reported to CMS, 2019-2025
18 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.07 · 2021: $211 · 2022: $511 · 2023: $440 · 2024: $1,211 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.43 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $929.22 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $638.62 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $281.54 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.23 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $164.69 | 2022 | |
| Travere Therapeutics, INC. | $164.12 | 2024 | |
| Ardelyx, INC. | $160.83 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Lilly USA, LLC | $133.44 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $99.07 | 2019 | |
| Akebia Therapeutics INC | $97.09 | 2021-2024 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $77.96 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $40.22 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $36.32 | 2023-2024 | Terlivaz |
| Glaxosmithkline, LLC. | $36.03 | 2021-2023 | Benlysta |
| Amgen INC. | $31.48 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.59 | 2024 | Jynarque |
| Bard Peripheral Vascular, INC. | $17.32 | 2023 | |
| Biodelivery Sciences International, INC. | $14.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.